BMRN (BioMarin Pharmaceutical) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BMRN BioMarin Pharmaceutical Inc BMRN
79 GF Score
Price $63.92
GF Value $85.29
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioMarin Pharmaceutical  (NAS:BMRN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


BioMarin Pharmaceutical Cyclically Adjusted PB Ratio Related Terms


BioMarin Pharmaceutical Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Cyclically Adjusted PB Ratio Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.14 5.24 4.43 2.74 2.31

BioMarin Pharmaceutical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.26 2.19 2.38 2.19 2.16

BMRN vs MDGL, CORT, ARWR: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, BioMarin Pharmaceutical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioMarin Pharmaceutical Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BioMarin Pharmaceutical's Cyclically Adjusted PB Ratio falls into.


BMRN
79GF Score
BioMarin Pharmaceutical Inc BMRN
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

BioMarin Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, BioMarin Pharmaceutical's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=32.664/333.9520*333.9520
=32.664

Current CPI (Jun. 2026) = 333.9520.

BioMarin Pharmaceutical Quarterly Data

Book Value per Share CPI Adj_Book
201609 15.410 241.428 21.316
201612 16.023 241.432 22.163
201703 15.978 243.801 21.886
201706 15.952 244.955 21.748
201709 16.032 246.819 21.692
201712 15.972 246.524 21.636
201803 15.890 249.554 21.264
201806 16.253 251.989 21.540
201809 16.385 252.439 21.676
201812 16.650 251.233 22.132
201903 16.403 254.202 21.549
201906 16.502 256.143 21.515
201909 17.118 256.759 22.264
201912 17.362 256.974 22.563
202003 17.924 258.115 23.190
202006 17.868 257.797 23.146
202009 22.336 260.280 28.658
202012 22.593 260.474 28.966
202103 22.784 264.877 28.726
202106 23.137 271.696 28.439
202109 23.240 274.310 28.293
202112 23.222 278.802 27.816
202203 23.749 287.504 27.586
202206 24.291 296.311 27.377
202209 24.585 296.808 27.662
202212 24.715 296.797 27.809
202303 24.835 301.836 27.477
202306 25.420 305.109 27.823
202309 26.000 307.789 28.210
202312 26.254 306.746 28.583
202403 26.736 312.332 28.587
202406 27.771 314.175 29.519
202409 28.409 315.301 30.089
202412 29.660 315.605 31.384
202503 30.213 319.799 31.550
202506 31.391 322.561 32.500
202509 31.529 324.800 32.417
202512 31.654 324.054 32.621
202603 32.142 330.213 32.506
202606 32.664 333.952 32.664

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is BioMarin Pharmaceutical (BMRN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of $63.92 is trading 25.1% below its estimated GF Value™ of $85.29. GuruFocus considers BioMarin Pharmaceutical to be Modestly Undervalued.

Key valuation signals for BMRN:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $85.29 vs. price of $63.92 (25.1% below fair value)
  • GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
79GF Score

Get the complete analysis for BMRN

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$63.92
Price
$85.29
GF Value